B
Bull
Bull · 25%SYBX
$1.87
シナリオ価格
$0.560
-0.280 (-50.00%)終値時点
Loading chart…
- High
- 0.777
- Open
- 0.777
- VWAP
- 0.63
- Vol
- 3.57M
- Mkt Cap
- 18.15M
- Low
- 0.560
- Amount
- 2.26M
- EV/EBITDA, TTM
- 0.00
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Analyst Ratings (1)
Buy
1 Buy
0 Hold
0 Sell
Current: 0.56
安値
—
平均
—
高値
—
HC Wainwright & Co.
Hold
—
2024-03-20
HC Wainwright & Co.
2024-03-20
目標株価
—
Hold
HC Wainwright & Co.
Strong Sell
—
2024-02-09
HC Wainwright & Co.
2024-02-09
目標株価
—
Strong Sell
Leerink Partners
Hold
$1
2024-02-09
Leerink Partners
2024-02-09
目標株価
$1
Hold
Chardan Capital
Hold
—
2024-02-09
Chardan Capital
2024-02-09
目標株価
—
Hold
Alliance Global Partners
Strong Buy
$30
2023-12-11
Alliance Global Partners
2023-12-11
目標株価
$30
Strong Buy
バリュエーション指標
The current forward P/E ratio for Synlogic Inc (SYBX) is -2.49, compared to its 5-year average forward P/E of -1.88.
Alphio AI Price Scenarios for SYBX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SYBX
イベントタイムライン
ニュース
SYBX FAQ — answered by Alphio AI
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
1 analysts cover SYBX: 1 rate it Buy, 0 Hold and 0 Sell.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。